CBPO  China Biologic Products Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

3.01B

Vuru Grade

72.45/100

Current Price

$112.02
+0.27 (+0.24%)

Growth Price

$39.28
Overvalued by 64.94%

Stability Price

$21.88
Overvalued by 80.47%

Company Metrics

  • P/E 32.3
  • P/S 9.27
  • P/B 6.77
  • EPS 3.47
  • Cash ROIC 27.80%
  • Cash Ratio 2.02
  • Dividend 0 / 0%
  • Avg. Vol. 250,712.00
  • Shares 26.87M
  • Market Cap. 3.01B

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

China Biologic Products Inc. Profit Climbs 23% In Q2
Nasdaq - Aug 4, 2016
The company said its bottom line rose to $35.17 million, or $1.26 per share. This was higher than $28.58 million, or $1.06 per share, in last year's second quarter.
China Biologic Products Inc.: China Biologic Reports Financial Results for the ... - The Wall Street Transcript
China Biologic Products Inc versus Ionis Pharmaceuticals Inc Head to Head Compare
CML News - Jul 22, 2016
China Biologic Products Inc has a substantially higher fundamental rating then Ionis Pharmaceuticals Inc which has an impact on the head-to-head comparison.
China Biologic Products Inc versus Exelixis Inc Head to Head Compare
CML News - Aug 26, 2016
China Biologic Products Inc has a substantially higher fundamental rating then Exelixis Inc which has an impact on the head-to-head comparison.
China Biologic Products Inc. (CBPO) Upgraded to Buy by Zacks Investment Research
BBNS - Aug 10, 2016
China Biologic Products logo China Biologic Products Inc. (NASDAQ:CBPO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.
China Biologic Products Inc. (CBPO) Insider Zhijing Cbpo Liu Sells 1968 Shares
Community Financial News - Aug 17, 2016
China Biologic Products logo China Biologic Products Inc. (NASDAQ:CBPO) insider Zhijing Cbpo Liu sold 1,968 shares of the business's stock in a transaction dated Monday, August 15th.
Revenue Update on China Biologic Products Inc(NASDAQ:CBPO) - Trade Calls
China Biologic Products, Inc. (NASDAQ:CBPO) Trading Down - Insiders Are Selling - Finance Daily
China Biologic Products Breaks Below 200-Day Moving Average - Notable for CBPO
Nasdaq - Aug 18, 2016
In trading on Thursday, shares of China Biologic Products Inc (Symbol: CBPO) crossed below their 200 day moving average of $118.26, changing hands as low as $112.51 per share.
Matthews International Capital Management Lowers stake in China Biologic ...
TheFounders Daily - Aug 26, 2016
China Biologic Products Inc (CBPO) : Matthews International Capital Management reduced its stake in China Biologic Products Inc by 64.34% during the most recent quarter end. The investment management company now holds a total of 33,500 shares of ...
Rudman Errol M Decreased Stake in China Biologic Prods INC (NASDAQ:CBPO) by $5 ... - Press Telegraph
Option Market: China Biologic Products Inc Risk Hits A Depressed Level
CML News - Aug 17, 2016
This is a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for China Biologic Products Inc (NASDAQ:CBPO) .
Jefferies Group Reiterates $136.00 Price Target for China Biologic Products ...
BBNS - Aug 5, 2016
China Biologic Products logo China Biologic Products Inc. (NASDAQ:CBPO) had its target price boosted by Jefferies Group from $136.00 to $155.00 in a note issued to investors on Friday.
China Biologic Products Inc (CBPO) Releases Earnings Results, Beats ... - Market Digest
China Biologic Products' (CBPO) CEO David Gao on Q2 2016 Results - Earnings ... - Seeking Alpha
Credit Suisse Downgrades China Biologic Products To Neutral
Benzinga - Mar 1, 2016
Credit Suisse's Iris Wang downgraded the rating on China Biologic Products Inc (NASDAQ: CBPO) to Neutral, while raising the price target to HK$129.